Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mol Immunol. 2021 Feb;130:20-30. doi: 10.1016/j.molimm.2020.11.016. Epub 2020 Dec 19.
Inflammatory bowel diseases (IBDs) may result from mutations in genes encoding for innate immunity, which can lead to exacerbated inflammatory response. Although some mono-targeted treatments have developed in recent years, IBDs are caused through several pathway perturbations. Therefore, targeting all these pathways is difficult to be achieved by a single agent. Moreover, those mono-targeted therapies are usually expensive and may cause side-effects. These limitations highlight the significance of an available, inexpensive and multi-targeted dietary agents or natural compounds for the treatment and prevention of IBDs. Curcumin is a multifunctional phenolic compound that is known for its anti-inflammatory and immunomodulatory properties. Over the past decades, mounting experimental investigations have revealed the therapeutic potential of curcumin against a broad spectrum of inflammatory diseases including IBDs. Furthermore, it has been reported that curcumin directly interacts with many signaling mediators implicated in the pathogenesis of IBDs. These preclinical findings have created a solid basis for the assessment of the efficacy of curcumin in clinical practice. In clinical trials, different dosages e.g., 550 mg /three times daily-1month, and 1 g /twice times daily-6month of curcumin were used for patients with IBDs. Taken together, these findings indicated that curcumin could be employed as a therapeutic candidate in the treatment of IBDs. Moreover, it seems that overcome to current limitations of curcumin i.e., poor oral bioavailability, and poor oral absorption with using nanotechnology and others, could improve the efficacy of curcumin both in pre-clinical and clinical studies.
炎症性肠病（IBD）可能是由于编码先天免疫的基因发生突变引起的，这可能导致炎症反应加剧。尽管近年来已经开发出一些针对单一靶点的治疗方法，但 IBD 是由多种途径的紊乱引起的。因此，单一药物很难针对所有这些途径。此外，这些单靶点治疗方法通常昂贵并且可能引起副作用。这些局限性突显了一种可用的、廉价的、多靶点的饮食剂或天然化合物在治疗和预防 IBD 方面的重要性。姜黄素是一种多功能酚类化合物，以其抗炎和免疫调节特性而闻名。在过去的几十年中，越来越多的实验研究揭示了姜黄素对包括 IBD 在内的广泛炎症性疾病的治疗潜力。此外，据报道，姜黄素直接与许多参与 IBD 发病机制的信号转导介质相互作用。这些临床前发现为评估姜黄素在临床实践中的疗效奠定了坚实的基础。在临床试验中，不同剂量的姜黄素（例如，IBD 患者每天服用 550 毫克/三次，持续 1 个月，每天服用 1 克/两次，持续 6 个月）用于治疗 IBD 患者。总之，这些发现表明姜黄素可作为治疗 IBD 的治疗候选物。此外，似乎克服了姜黄素目前的局限性，即口服生物利用度差和口服吸收差，通过使用纳米技术等，可以提高姜黄素在临床前和临床研究中的疗效。
